Evidence map›Paper›PMID 36852863›Full record

ArticleGenome biology and evolution2023

Systematic Exploration of SARS-CoV-2 Adaptation to Vero E6, Vero E6/TMPRSS2, and Calu-3 Cells.

Pakorn Aiewsakun, Worakorn Phumiphanjarphak, Natali Ludowyke, Priyo Budi Purwono, Suwimon Manopwisedjaroen, Chanya Srisaowakarn, Supanuch Ekronarongchai, Ampa Suksatu, Jirundon Yuvaniyama, Arunee Thitithanyanont

Open access · goldAbstract read
In one paragraph

Article in Genome biology and evolution, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Usambarensine fromACS omega · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Pakorn AiewsakunDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-5665-4041
Worakorn PhumiphanjarphakDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Natali LudowykeDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Priyo Budi PurwonoDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Suwimon ManopwisedjaroenDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Chanya SrisaowakarnDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Supanuch EkronarongchaiDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Ampa SuksatuDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Jirundon YuvaniyamaDepartment of Biochemistry and Center for Excellence in Protein and Enzyme Technology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Arunee ThitithanyanontDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Mahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally, and scientists around the world are currently studying the virus intensively in order to fight against the on-going pandemic of the virus. To do so, SARS-CoV-2 is typically grown in the lab to generate viral stocks for various kinds of experimental investigations. However, accumulating evidence suggests that such viruses often undergo cell culture adaptation. Here, we systematically explored cell culture adaptation of two SARS-CoV-2 variants, namely the B.1.36.16 variant and the AY.30 variant, a sub lineage of the B.1.617.2 (Delta) variant, propagated in three different cell lines, including Vero E6, Vero E6/TMPRSS2, and Calu-3 cells. Our analyses detected numerous potential cell culture adaptation changes scattering across the entire virus genome, many of which could be found in naturally circulating isolates. Notable ones included mutations around the spike glycoprotein's multibasic cleavage site, and the Omicron-defining H655Y mutation on the spike glycoprotein, as well as mutations in the nucleocapsid protein's linker region, all of which were found to be Vero E6-specific. Our analyses also identified deletion mutations on the non-structural protein 1 and membrane glycoprotein as potential Calu-3-specific adaptation changes. S848C mutation on the non-structural protein 3, located to the protein's papain-like protease domain, was also identified as a potential adaptation change, found in viruses propagated in all three cell lines. Our results highlight SARS-CoV-2 high adaptability, emphasize the need to deep-sequence cultured viral samples when used in intricate and sensitive biological experiments, and illustrate the power of experimental evolutionary study in shedding lights on the virus evolutionary landscape.

Indexed as

COVID-19SARS-CoV-2AnimalsChlorocebus aethiopsGlycoproteinsVero CellsGlycoproteinsCalu-3COVID-19experimental evolutionary studySARS-CoV-2Vero E6Vero E6/TMPRSS2

Identifiers

PMID36852863
PMCPMC10078795
OpenAlexW4322616921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.